Background. Methylphenidate (MPH) action may improve executive function and motor function. Effects of MPH on balance function in older adults were investigated.
F ALLS in older adults are the leading cause of hip fractures (1), of injury-related visits to emergency departments (2) , and of accidental death (3) . Age-related deterioration in gait and balance is a major contributor to falls in older adults. In fact, alterations in balance control during quiet standing can be objectively measured by comparing healthy older adults and young adults (4) and fallers and nonfallers (5) . An additional factor that may limit balance control and gait in older adults is the simultaneous performance of a motor or cognitive task (4, 6) . The premise is that when two tasks are performed simultaneously and require more than the total information processing capacity of a person, performance on either or both tasks deteriorates. The dual-task (DT) paradigm is used in part as a measure of executive function (EF), which refers to higher cognitive processes that are used to allocate attention among different tasks that are performed simultaneously. Impaired EF abilities among older adults may reduce his/ her ability to compensate for age-related changes in gait by compromising safe negotiation in complex everyday environments (7, 8) and apparently leads to greater fall risk (9) (10) (11) (12) (13) . EF has been found to be related to past falls (13, 14) ; EF and gait variability during DT condition predicted future falls and multiple falls (15) , suggesting that higher level cognitive functions such as those regulated by the frontal lobes are apparently needed for safe everyday navigation that demands multitasking. MRI studies show associations between history of falls and age-related changes in the prefrontal cortex and brain regions related to EF (16) . Recent studies show that severe cerebral white matter hyperintensities burden associated with poor EF and sensorimotor performance (16, 17) was related to an increased risk of multiple falls or injurious falls during the 1-year follow-up (18) . Their analysis suggests that white matter hyperintensities, cognitive (executive) functioning, and sensorimotor impairments were independently associated with falls (18) . Li and colleagues (19) found that healthy older adults who completed five sessions of nonpharmacological cognitive DT training showed significant improvements in body sway during single-support balance, and center of gravity alignment during double-support dynamic balance, compared with an untrained control group. Therefore, it was suggested that improvements in frontal EF improve gross motor performance by improving planning, control, and execution of movements, and thus are likely to improve gait function and reduce risk of falls.
Our study was motivated by the earlier studies and randomized control studies where single dose of methylphenidate (MPH) improved EF (e.g., Go-NoGo accuracy), mobility (e.g., Timed Up and Go times), and gait (e.g., stride time variability) in relatively healthy older adults (20) . Other studies showed that a single dose of MPH improved mobility and gait (e.g., the number of steps and time in the stand-walk-sit test and the Tinetti scale score [21] ); gait speed, stride variability, Timed Up and Go times as well as attention; and EF that showed a trend towards improvement (22) in Parkinson's patients. Moreau and colleagues (23) . found that MPH improved gait hypokinesia and freezing in patients with advanced Parkinson's disease who suffered from severe gait disorders and freezing of gait, despite optimized treatment of motor fluctuations with dopaminergic drugs and subthalamic stimulation.
Given the known deficits in attention and EF in older adults, as well as evidence for benefits of MPH for divided attention and evidence suggesting that gait and balance control requires attention, we sought to investigate the effects of single dose of MPH on gait and postural stability in older adults, in both single-task (ST) and DT conditions. The rationale for using MPH to treat fall risk is based, in part, on the fact that MPH may improve EF, which generally declines with aging (24) , and thus may improve mobility and unstable gait and reduce fall risks in older people. The mechanism of action of MPH is dopamine reuptake inhibition, increasing extracellular dopamine levels in the striatum (25) , thereby improving frontal brain activation (26) . MPH has also been suggested to have a direct influence on areas of the brain that deal directly with motor and balance control. It was shown that MPH modulates intracortical disturbed facilitatory and inhibitory motor circuits (27) and significantly changed the blood flow in the putamen, which is mainly involved in the regulation of motor behavior (28) .
Based on recent studies (20) (21) (22) (23) , we tested the following hypothesis: after administering a single dose of MPH, gait and postural stability of older adults will improve in both ST and DT conditions. Because walking, especially under DT conditions, where the participants are asked to switch attention between gait and a concurrent cognitive task, is a much more complex procedure that requires higher executive control, whereas measures of upright standing especially in ST are less complex, we hypothesized that gait, especially during DT conditions will be improved more than the simple tasks such as standing.
Methods

Study Design and Participants
Thirty healthy older adults (mean age = 74.9 ± 5.6) were recruited for the study. Participants were included based on the following criteria: aged 70 years or older and ability to walk independently at least 20 m, that is, without personal assistance or an assistive device. The exclusion criteria were as follows: (a) serious visual impairment (i.e., disorders of retina, glaucoma, cataract, and blindness caused by injury); (b) inability to ambulate independently; (c) score lower than 24 in Mini-Mental State Examination; (d) severe peripheral or compression/entrapment neuropathies; (e) symptomatic cardiovascular, musculoskeletal, or neurological disorders that may interfere with gait; and (f) under active treatment of cancer. Participants provided informed consent in accordance with approved procedures by the Helsinki Ethics Committee in Soroka Medical Center (Clinical Trials Registration number #NCT00817960).
Blinded Outcome Assessments
After eligibility was determined, volunteer participants were randomly assigned, using a table of random numbers, to either the intervention group, who received MPH drug treatment (experimental), or the placebo group (control) who received placebo MPH. The placebo pill was identical in appearance to the MPH pill. Each group had 15 participants. After completion of the baseline examination, the participants of both groups were given medication in a double-blinded, randomized fashion (10 mg of short-acting MPH to the experimental group and 10 mg of placebo to the controls). The dose of MPH selected was based on the facts that intake of 10 mg MPH showed improvement in gait parameters in Parkinson's patients (29) and was found to be beneficial on speed of processing and EF in patients with a primary brain tumor (30) . Additionally, MPH treatment in adults with attention-deficit or hyperactivity disorder is usually started with 10 mg/d and titrated up to higher dosage, depending on individual efficacy and tolerance (31) . The immediate benefit noted in patients participating in the single-dose open-label studies supported the rationale for the current trial. It therefore seemed interesting to determine whether lower doses could also improve balance and gait function in healthy older adults. The participants and the tester administering the examinations were blinded to group assignment. After completion of baseline examination, both study groups had an hour and a half break, followed by an identical testing procedure. Peak plasma concentration of MPH is obtained 1-3 hours after oral administration with a mean plasma half-life of 1.5-2.5 hours (32) . Participants were therefore tested 1.5-2 hours postdrug administration.
Postural Stability Protocol
The participants were instructed to stand upright on the force platform with the feet positioned as close as possible (heels and toes touching). A total of fourteen 30-second trials were conducted for two task conditions. The two task conditions were (a) ST-seven standing upright trials with the eyes closed and blindfolded and (b) DT-same as ST, whereas performing a memory attention-demanding task. During the DT trials, the participants were instructed to stand still and to listen to a collection of 15 words (one word every 2 seconds) played through a single speaker that was placed 2-3 m in front of them; we made sure they could clearly hear the sound. The instructions were "the first letter in the next collection of words must be always A (for example), please count the number of words that do not start with this letter while standing still." No specific attentional focus was instructed; the participants were asked to perform both tasks as best as they could. Participants were allowed to practice the cognitive task procedure prior to the test in ST and DT conditions to make sure they understood the instructions and became familiar with the test situation. After the completion of each of the seven DT trials, their task was to recall, from words they heard, the number of words that did not start with the specific letter that they had been given. The number of mistakes was counted in each of the seven trials (i.e., cognitive task errors) and presented as the total cognitive task errors in all trials because there were many cases in which participants had zero errors in ST and DT conditions. Balance measurements were collected with a Kistler 9287 single force platform (Kistler Instrument Corp, Winterthur, Switzerland), which measures the time-varying displacement of the center of pressure (CoP) under the participant's feet. The force platform data were sampled at a frequency of 100 Hz and stored on a hard disk for later processing. Force platform data were analyzed using automatic code written in Matlab (Math Works Inc, Cambridge, MA) to extract four well-established parameters of postural stability: (a) mediolateral (ML) CoP range (mm; ML sway range); (b) anterioposterior (AP) CoP range (mm; AP sway range); (c) mean velocity of CoP sway (mm/s); and (d) sway area (mm 2 )-the elliptical area of the CoP points. These parameters were computed for each participant's trials and then averaged for each set of seven trials to obtain an average value for each parameter and for each participant in each experimental condition.
After a 10-minute break, gait was measured using the narrow base walk test (33) , modified for clinical use. Participants were asked to walk within a narrow path (6 m long) first without and then with a concurrent cognitive task (ST and DT), always in the same order. The test incorporated measurement of lateral instability during gait. The width of the narrow path was normalized to 50% of the distance between the participant's anterior superior iliac spines plus the width of the participant's shoe. This produces a similar challenge for individuals with different body morphologies. The narrow path was outlined by two narrow 6-m black mattresses on the walking surface; the participants were instructed to walk within the path without stepping on the black mattresses. To minimize the effect of learning, participants were allowed to practice two to three times to become familiar with the test situation. All six trials were videotaped using a video camera that was placed 2 m in front of the walking path and 1.5 m high to detect trial time and step errors during the test.
Step error is defined as every step where the participant's shoes step outside the narrow path, touching the black mattresses outlining the sides of the narrow base walkway. For the cognitive task, three different types of cognitive tasks were used to minimize learning effects; in the first trial, participants were asked to say the days of the week backwards, the months of the year backwards in the second trial, and to count down in increments of 5 from 100 to 50 in the third trial, always in the same order. Under the DT condition, no specific attentional focus was instructed, and participants were asked to perform both tasks as best as they could. Participants were allowed to practice the cognitive tasks prior to the test in both ST (e.g., sitting) and DT conditions to become familiar with the test conditions. The videotapes were later analyzed by a tester who was blinded to group assignment to count the number of steps, measure trial times, detect steps errors, calculate trial velocity (i.e., 6 m divided by the trial time), and calculate the step error rate (i.e., the ratio between the number of step errors divided by the number of steps for each trial). The test-retest agreement of Narrow Base Walking Test (NBWT) found to be high for all variables; Interclass correlation coefficient (ICC), (1,2) = 0.77-0.92 in ST and ICC (1,2) = 0.78-0.92 in DT (unpublished data). Cognitive task error rates were also counted during the ST (i.e., sitting) and DT trials (i.e., while walking). The cognitive task error rate is the number of cognitive task errors divided by the number of cognitive tasks during each trial. All NBWT parameters were computed for each participant's trials and then averaged for each set of three trials to obtain an average value for each parameter and for each participant in ST and DT conditions.
Sample Size
Separate calculations were performed to determine sample size requirements based on postural stability (i.e., mean velocity in mm 2 /s) and 6-m narrow base walking (i.e., step error rate and stride velocity in m/s). For both calculations, the probability of Type I error was .05 and probability of Type II error was .2. For the first hypothesis, we used data presented by Melzer and colleagues (4); the mean velocity of postural sway of healthy older adults was 22.6 ± 7.6 mm/s in ST, whereas the mean velocity of postural sway of younger adults was 12 ± 4 mm/s. For a conservative estimation, we used a standard deviation of 7.6. Using the above numbers for a two-sided estimation at a significance level of 0.05 and 80% power, it was calculated that a minimum of nine older adults would be required to find significant differences. For the second hypothesis, we used both the mean step error rate and stride velocity during the 6-m narrow base walking test as presented by Kelly and colleagues (33) . They found that the mean step error rate of nine adults aged 60.1 ± 3.3 years was 6.6% ± 9.3 and 17.1% ± 12.8 for 13 older adults (69 ± 2.7 years); stride velocity was 1.1 ± 0.12 and 0.97 ± 0.14, respectively (32). Using the above numbers for a two-sided estimation at a significance level of 0.05 and 80% power, it was calculated that a minimum of 15 older adults would be required to find significant differences.
Data and Statistical Analyses
For statistical calculations, PASW Statistics version 15 was used (Somers, NY, version 15). Baseline characteristics of the experimental and control participants were compared using independent t test or Wilcoxon-signed rank test when data were not normally distributed (Shapiro-Wilk statistic). To test the first and second hypotheses, we applied a separate model where the dependent variables were the average values of the postural stability or gait stability parameters (a continuous one) and the independent variables were categorical: the group (experimental vs control) and time (pretest vs post-test). Because sway area and AP sway parameters were significantly different between groups during the baseline measures, we added to the model these two variables as a covariate. For the gait stability measures in DT condition, we applied separate models for each DT trial (Trials 1, 2, and 3) to explore which of the DT trials was most sensitive to the MPH intervention; the dependent variables were the gait stability parameters (continuous) and the independent variables (categorical): group (experimental vs control) and time (pretest vs post-test). If a significant interaction effect for time and DT trials was found for the DT trials, post hoc analyses (Fisher's least significant difference LSD test) were performed to explore which of the DT trials was the most difficult.
In addition, repeated measure analysis of variance was used to evaluate the interference effect of the concurrent attention-demanding task (e.g., DT cost) for each postural stability and NBWT parameter. These parameters in DT were normalized to ST within each participant (the proportionate difference was calculated as (( ) ) DT/ST´100 . For the number of cognitive task errors, there were many cases in which participants had zero errors in the ST conditions, and hence it was not possible to carry out the mathematical calculation. For this reason, we did not evaluate the overall interference effect for this parameter in ST and DT conditions. p values reported are based on two-sided comparisons. A p value of .05 was considered statistically significant.
For each parameter, the effect size (ES) of Hedge's g and the 95% confidence interval (CI) were calculated. The ES of g was calculated by taking the difference between the means of both groups divided by the average population standard deviation. To estimate the standard deviation for g, baseline estimated standard deviations of both groups were pooled. The following guidelines were used when interpreting correlation magnitude: 0.0-0.2 is considered small, 0.2-0.5 is considered moderate, 0.5-0.8 is considered large, and 0.8 and above excellent (34) .
Results
As shown in Figure 1 , 30 of 41 older adults enrolled in the study met the entry criteria, agreed to participate, and were randomized. At baseline, the experimental (n = 15) and control (n = 15) groups had similar characteristics, postural sway, and gait parameters apart from AP sway range (Table 1 ). There were no dropouts in either group and no adverse events of drug treatment were experienced.
For the postural stability parameters during ST and DT conditions, no significant interaction effect between group and time was observed apart from a significant Group × Time interaction that was found for AP sway range in DT condition (F = 1.7, p = .05, ES = 0.20), which indicates significantly improved stability in the experimental group with a small effect size during the DT but not during the ST. In addition, a significant main effect for time was revealed in mean velocity and sway area during ST condition (F = 4.5, p = .04 and F = 4.0, p = .05, respectively) and ML sway range, mean velocity, and sway area during DT condition (F = 6.4, p = .016; F = 19.6, p = .001; and F = 10.6, p = .003, respectively), which was driven by a substantial improvement over time in both study groups ( Table 2) .
The effects of MPH on the average values of the gait trials of the experimental and control participants are summarized in Table 3 . MPH did not have significant Group × Time interaction on trial time and trial velocity during ST condition. In the number of step errors, however, a significant Group × Time interaction was found in the ST condition (F = 4.5, p = .02, ES = 0.4), which indicates a significant improvement in the experimental group with a moderate effect size. The analysis revealed a 57% reduction in the number of step errors in the experimental group, with no equivalent improvement in placebo controls (Table 3 , panel A). In the DT condition, a significant Group × Time interaction effect was found for trial time, trial velocity, and number of step errors after taking MPH medication (F = 6.1, p = .02, ES = 0.42; F = 5.2, p = .04, ES = 0.28; and F = 5.7, p = .02, ES = 0.74, respectively), with 55% reduction in the number of step errors in the experimental group, with no equivalent improvement in the control group (Table 3, panel B) . Also, a significant Time × Trial interaction effect was found for average values of cognitive task error rates in ST and DT trials (F = 3.5, p = .04 and F = 4.2, p = .03, respectively) and for gait velocity in the DT trials (F = 2.3, p = .05). Post hoc analysis revealed that the gait velocity during the second DT trial tended to be slower compared with the first and third DT trials (p = .06 and p = .16, respectively). More cognitive task errors occurred during the second DT trial (e.g., saying the months of the year backward) compared with the first and third DT trials (p = .05 and p = .48, respectively); this indicates that the second DT trial was the most difficult DT trial (Table 4 ).
In addition, Table 4 reveals a significant Group × Time interaction effect for the trial velocity in all three DT condition trials (F = 5.3, p = .03; F = 6.2, p = .01; and F = 7.4, p = .009, respectively), which indicates that an equivalent improvement in gait velocity occurred in all DT trials in the experimental group. Table 4 also reveals a significant Group × Time interaction effect for all three variables representing motor performance in the third trial; trial time, trial velocity, and the number of steps improved in the experimental group only (F = 6.7, p = .01; F = 7.4, p = .009; and F = 9.7, p = .004, respectively), which indicates that a learning effect occurred during the trials after MPH treatment.
A significant main effect for time was revealed in gait stability parameters, where significant improvement in both groups was found during the post-testing sessions. For example, Table 4 shows that the trial velocity was significantly improved in all DT condition trials (F = 6.6, p = .01; F = 5.7, p = .02; and F = 6.2, p = .001, respectively). For the cognitive task error rate during the postural stability and narrow base walking tests in ST and DT conditions, no significant interaction effect between group and time or significant main effect for time were observed (Tables 2, 3 , and 4). Also, nonstatistically significant Group × Time interaction effects for the DT costs (DT:ST ratio) were found for both postural sway and gait parameters in both the average values and for each of the three DT trials (Table 5 ).
Discussion
In this study, we sought to investigate the effects of a single dose of MPH on postural stability and gait stability in healthy older adults, in ST and DT conditions. In this study, a single dose of 10 mg MPH improved gait stability by reducing the number of step errors during the narrow base walking test in ST and DT tasks, with an equivalent Comparison of baseline and postintervention between the two groups based on repeated measures ANOVA (Test × Group).
change in trial times and trial velocity in DT condition. We found no significant improvement in postural stability during ST condition with small yet significant improvement in postural stability during DT condition (e.g., AP sway). The present findings are similar to the results of a previous study in older adults (20) . In that study, a single dose of MPH improved mobility, gait, and EF in older healthy adults (20) . Also, nonpharmacological behavioral intervention showed significant improvements in the speed, variability, and ML body sway during single-support balance and in the center of gravity alignment values in the AP dimension in double-support balance (19) . The motor benefit of MPH was also obtained in Parkinson's patients (21) ; three months of MPH treatment improved balance and mobility, number of freezing episodes, and the Unified Parkinson's Disease Rating Scale part III score in the absence of l-DOPA (21). Auriel and colleagues (22) found that a single dose of MPH improved gait speed, decreased Timed Up and Go times, and reduced stride time variability. Also, Moreau and colleagues (23) found that MPH improved gait hypokinesia and freezing in patients with Parkinson's disease. Gehring and colleagues (30) found a beneficial effect following 4 weeks of MPH treatment on speed of processing and EF requiring divided attention in patients with a primary brain tumor.
This study extends those previous findings, showing that a single dose of MPH improves gait stability and gait velocity, especially in DT condition in healthy older adults. During the narrow base walking test, the participants were instructed to walk within a narrow path between two black mattresses without stepping on them, which involves planning and executing a motor task. This is a complex procedure, especially walking under DT conditions where the participants were asked to switch attention between motor task (i.e., gait) and a concurrent cognitive task that requires higher EF abilities. Gait velocity, especially in the DT condition, represents the EF abilities of walking and concurrently performing a cognitive task. In our study, gait velocity was improved after MPH treatment (Tables 3 and 4) . Furthermore, our results suggest that trial-to-trial learning effect resulting from MPH treatment occurred during the DT walking trials (Table 4) , where trial time, gait velocity, and number of step errors was improved, particularly during the third DT trial. Gait velocity is a measure that has been suggested as especially sensitive to dopamine uptake (28) . In a less complex procedure, for example, upright standing during ST, our study revealed no significant improvement; in DT standing trials; however, there was a small yet significant improvement in AP sway. This may suggest that MPH is able to improve function especially in complex tasks that require higher executive control, whereas simple tasks that require lower executive control showed less benefit from MPH treatment. Our results add to a growing body of evidence showing that MPH may have a role as a therapeutic option for improving gait and reducing fall risk in older adults, especially in "real-life" situations, where the requirement to walk commonly occurs under more complicated circumstances with cognitive attention focused elsewhere (e.g., watching traffic, talking) and not on performing a specific motor task.
The findings could be interpreted in two ways: (a) MPH treatment as a cognition-enhancing therapy helps to specifically improve walking in older adults and (b) MPH has a direct influence on motor function. Studies have found that nonfaller older adults perform better than fallers on tests of EF, have better gait and mobility, and perform better in tests that require a DT procedure (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . This suggests that central processing abilities, attentional capacity, and cognitive function are important factors for gait in older adults. According to this explanation, the enhanced attention that comes about as a result of MPH may lead to improved balance control during walking, especially in DT conditions. Our findings that MPH improves gait can be explained not just by its effect of attentional improvements but can also indicate that MPH has a direct influence on areas of the brain that deal with motor and balance control. MPH is a dopamine reuptake inhibitor, thereby increasing extracellular dopamine levels in the striatum, frontal, and prefrontal cortex areas of the brain (25) that are largely responsible for dual tasking and attention, may improve gait, similar to the way that dopaminergic medications modify postural control in Parkinson's disease. The study revealed no statistically significant changes in cognitive performance (e.g., cognitive task errors) in both study groups. This can be interpreted as practice effects that seem evident in the cognitive task errors even prior to the MPH treatment, where DT cognitive performance was not worse than ST, resulting from the fact that ST trials always preceded DT trials of the same type. Another option might be a ceiling effect, resulting from extremely easy cognitive tasks. This option is likely not the case; older adults in our sample reported that the cognitive tasks during the walking trials were extremely difficult for them. Furthermore, the results showed lower gait performance in DT compared with ST, which indicates that older adults in our study shifted their focus of attention away from gait and balance during the DT trials; thus, other mechanisms may have played a role. More specifically, the results show more step errors and slower gait during DT, whereas the cognitive performance did not decrease relative to an ST baseline where the focus of attention was explicitly directed toward the cognitive task itself. This may suggest that the "posture second" strategy took place, where healthy older adults focused more strongly on their cognitive performance than on their motor performance; this was associated with lower gait performance in DT, in line with the limited attentional capacity view (35) . Patterns of resource allocation may also differ by age and motor abilities; it might be that less healthy populations of older adults would demonstrate the "posture-first mechanism," focusing attention more strongly on their postural control than on their cognitive performance to avoid falls (6) .
Regarding the possibility that learning also occurred in the motor tasks, since ST trials always preceded the DT trials, our results showed decreased gait performance in the DT baseline data compared with the ST baseline data. This suggests that practice during the ST trials did not affect gait performance during the DT trials or perhaps diluted the DT effects on gait performance. This study has a number of limitations and thus should be interpreted with caution. First, the data came from a fairly small sample that was drawn from a defined relatively healthy community-based population. These results cannot be generalized to extremely weak or institutionalized elderly persons. Second, the easier word monitoring cognitive task during the standing trials and the fluency tasks during the gait trials introduced a confounder to the design of the experiment. Because passive word monitoring would not require EFs as much as fluency does, one cannot make strong conclusions about the relative efficacy of drug treatment effects for DT balance versus walking. A similarly demanding cognitive task requiring EF might result in stronger treatment-specific improvements for DT balancing.
In conclusion, a single dose of MPH was able to improve gait function in healthy older adults especially in complex tasks that require higher executive control. As noted earlier, this could also largely account for the effects of MPH on a sustained attention DT, but other mechanisms may have also played a role (e.g., direct effects on the motor system). Further study should involve larger sample sizes and less healthy populations of older adults and provide imagebased evidence (e.g., functional MRI) to explore areas of the brain after MPH medication during gait and standing imagery. Future studies may also wish to explore the specific patient factors that may be associated with responsiveness to MPH treatment, exploring different doses of MPH, and processing speed and EF. Our results support the potential of a large-scale double-blind, placebo-controlled trial to assess long-term treatment with MPH and its ability to lower fall rates in older populations.
